Thalys(SH:603716) Sou Hu Cai Jing·2025-12-27 18:17Core Viewpoint - The company, Selys Medical Technology Group Co., Ltd., is undergoing changes in its business scope and governance structure, with a focus on expanding into new product categories and preparing for a shareholder meeting to approve these changes [2][4][6]. Group 1: Stock Performance - As of December 26, 2025, Selys Medical's stock closed at 21.48 yuan, down 4.06% from the previous week's 22.39 yuan [1]. - The stock reached a high of 22.5 yuan and a low of 21.16 yuan on December 25, 2025 [1]. - The company's current total market capitalization is 4.515 billion yuan, ranking 24th out of 32 in the pharmaceutical commercial sector and 3628th out of 5178 in the A-share market [1]. Group 2: Corporate Announcements - The fifth board of directors held its 24th meeting on December 22, 2025, where it approved two key resolutions: one to expand the company's business scope and another to convene the first extraordinary general meeting of shareholders in 2026 [2][4]. - The company plans to hold the first extraordinary general meeting of shareholders on January 7, 2026, with both on-site and online voting options available [3][6]. - The proposed expansion of the business scope includes health products, cosmetics, daily chemical products, personal hygiene products, special medical purpose formula foods, pre-packaged foods, health foods, and internet sales [4][6]. Group 3: Corporate Governance - The company's articles of association were revised in December 2025, establishing it as a perpetual joint-stock company with a registered capital of 210,139,246 yuan [5]. - The articles outline shareholder rights and obligations, the powers and rules of the shareholders' meeting, responsibilities of the board of directors and supervisors, and financial accounting policies [5]. - The company aims for a cash dividend priority in profit distribution, with a commitment to distribute no less than 30% of the average distributable profit over the last three years [5].